Page last updated: 2024-11-12
ptr 3173
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
PTR 3173: amino acid sequence in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 9919857 |
MeSH ID | M0379330 |
Synonyms (24)
Synonym |
---|
n4.1-(2-amino-2-oxoethyl)-cyclo(4-aminobutanoyl-4-aminobutanoyl-l-phenylalanyl-l-tryptophyl-d-tryptophyl-l-lysyl-l-threonyl-l-phenylalanyl) |
veldoreotide [inn] |
veldoreotide [who-dd] |
252845-37-7 |
ptr 3173 |
veldoreotide [usan] |
dg-3173 |
glycinamide, n-(4-amino-1-oxobutyl)-l-phenylalanyl-l-tryptophyl-d-tryptophyl-l-lysyl-l-threonyl-l-phenylalanyl-n2-(3-carboxypropyl)-, (7->1)-lactam |
1Z83587HBN , |
veldoreotide |
2-[(3s,6s,9s,12r,15s,18s)-9-(4-aminobutyl)-6-(1-hydroxyethyl)-12,15-bis(1h-indol-3-ylmethyl)-2,5,8,11,14,17,20,25-octaoxo-3,18-bis(phenylmethyl)-1,4,7,10,13,16,19,24-octazacyclooctacos-1-yl]acetamide |
somatoprim |
cor-005 |
dg3173 |
ptr-3173 |
gtpl8487 |
dg 3173 |
unii-1z83587hbn |
DB12777 |
2-[(3s,6s,9s,12r,15s,18s)-9-(4-aminobutyl)-3,18-dibenzyl-6-[(1r)-1-hydroxyethyl]-12,15-bis(1h-indol-3-ylmethyl)-2,5,8,11,14,17,20,25-octaoxo-1,4,7,10,13,16,19,24-octazacyclooctacos-1-yl]acetamide |
EX-A7913 |
Q27253298 |
CS-0012831 |
HY-P0024 |
Research Excerpts
Dosage Studied
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (12)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 6 (50.00) | 29.6817 |
2010's | 6 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.87
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.87) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 5 (38.46%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 8 (61.54%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |